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placebo group (difference in cost 4247,36 USD). Incremental
CER was 20 360,90 USD for one patient with viral load <50
copies/ml (16 462,65–41 640,81 USD in sensitivity analysis).
Cost of one patient with achieved viral load <50 copies/ml was
lower for ETR group. CONCLUSIONS: According to the model
ETR seems to be much more effective than placebo with afford-
able CER incremental ratio. Evaluation of ETR treatment cost-
effectiveness in common practice in Russian health care is
needed.
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OBJECTIVES: It is estimated that annually 300,000 cases of
rotavirus-induced gastroenteritis (RVGE) occur in children aged
up to 5 years in France. RIX4414 (Rotarix™ GlaxoSmith-
Kline), a two-dose oral vaccine against rotavirus infection, has
been shown to be highly effective against severe RVGE. A
recent study (Melliez et al, Vaccine 2008) concluded that
rotavirus vaccination was not cost-effective according to French
Public Health context. We evaluated the cost-effectiveness of
general vaccination against rotavirus using Rotarix™ in France
using an updated model. We investigated the differences in
modelling approaches and resultant cost-effectiveness conclu-
sions. METHODS: A Markov model simulated RVGE events
and the associated outcomes and costs in a birth cohort of
children in France (n = 750,000), adjusting for age distribution
and seasonality of infection. Costs and outcomes were esti-
mated from a limited societal perspective (without indirect
costs). The primary outcome measure was the incremental cost
per quality-adjusted life year (QALY). RESULTS: Vaccination
with Rotarix™ incurred an incremental cost of €44,583/QALY
at a public price of €57 per vaccine dose. Univariate sensitivity
analyses showed that the results were largely inﬂuenced by the
discount rate for beneﬁts, nosocomial rotavirus infection
burden, hospital costs, and vaccine efﬁcacy and cost. The
acceptability curve indicated that 60% of the results were
under the threshold of €50,000/QALY. Comparing these results
with those of Melliez et al, the apparent discrepancy can be
largely explained by differences in model structure and data
input values including: different at-risk period and time
horizon; different vaccine efﬁcacy; different unit cost data; dif-
ferent disease duration and disutility values. CONCLUSIONS:
These results demonstrate that a generalized vaccination strat-
egy with Rotarix™ would be cost-effective in France from a
societal perspective without including indirect costs; however
there is a need for agreed standards to improve comparability
of results from different studies.
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OBJECTIVES: The aim of this study is to evaluate the long-
term economic cost-effectiveness and clinical impact of univer-
sal infant vaccination of 7-valent pneumococcal conjugate
vaccine (PCV7) in Taiwan by using a dynamic SIR model.
METHODS: Recently, there are lots of interests surrounding
the cost-effectiveness of PCV7 against pneumococcal diseases.
Particularly, the quantiﬁcation of the herd-immunity effects
caused by this vaccine has been widely discussed. A cohort
model in our previous study indicated that the universal PCV7
vaccination in Taiwan is a cost-effective intervention with
an incremental cost per life year gained of NT344,928
(US$11,227), preventing thousands of IPD cases over a 10-year
horizon. However, this model cannot dynamically capture age-
dependent force of infection associated with the effects of dif-
ferent contact patterns on pre- and post-vaccination. Hence, the
herd-immunity externalities cannot be correctly estimated,
which would bias our ﬁndings. To reassess the cost-effectiveness
of this vaccine, we incorporated a dynamic realistic age-
structured Susceptible-Infected-Recovered (SIR) model that can
account for both the direct and indirect (i.e. herd-immunity
effects) beneﬁts of vaccination. All pre-vaccination parameters
such as age-speciﬁc disease incidence, mortality, seroprevalence
data, and cost associated with the treatment of pneumococcal
diseases were obtained from the National Health Insurance
(NHI) Database and published literature where available. A
societal perspective and a health care payer’s perspective were
adopted. Various vaccine strategies including hypothetical sce-
narios were investigated. One-way and multi-way sensitivity
analyses were also performed to evaluate model robustness.
RESULTS: Our model suggests that universal PCV7 vaccina-
tion has a considerable impact on the reductions of the mor-
bidity and incidence related to pneumococcal diseases where
the herd-immunity effects are more precisely quantiﬁed using
dynamic SIR model. CONCLUSIONS: A universal infant vac-
cination with PCV7 is a cost-effective intervention from a
dynamic perspective and its continuous vaccination in Taiwan
is greatly encouraged.
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OBJECTIVES: The Phase III TITAN trial (TMC114-C214)
evaluated darunavir/ritonavir (DRV/r) 600/100 mg bid versus
lopinavir/ritonavir (LPV/r) 400/100 mg bid in treatment-ex-
perienced, LPV/r-naïve, HIV-infected adults. We determined the
cost-effectiveness of DRV/r versus LPV/r from the perspective of
British, Swedish, Italian and Belgian payers in the TITAN trial
subgroup with at least one IAS-USA primary protease inhibitor
(PI) mutation at baseline. These patients had less advanced HIV
disease and a broader degree of prior PI use/failure (0 = 2) than
those in the DRV Phase IIb POWER trials (= 2). METHODS: An
existing Markov model containing 6 CD4+ T-cell count (CD4
count)-deﬁned health states and a “death” state was adapted to
the abovementioned countries. Baseline demographics and CD4
count distribution, antiretroviral drug usage, virologic and
immunologic response rates and matching transition probabili-
ties were based on TITAN trial data collected in the modelled
subgroup during the ﬁrst 48 weeks of therapy and from pub-
lished literature. Patients were assumed to switch to a follow-up
combination therapy after failure. For each model state, utility
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values and mortality rates were obtained from published litera-
ture. Costs in each state were obtained from local observational
studies and ofﬁcial, local unit costs or from published literature.
A lifetime horizon was taken. Discount rates varied according
to local guidelines. RESULTS: The base-case incremental cost-
utility was €18213 (£13111)/QALY, €7605 (SEK 70379)/QALY,
€17592/QALY and €7990/QALY in the UK, Sweden, Italy and
Belgium, respectively. Assuming a threshold of €30,000/QALY,
DRV/r remained cost-effective over most parameter ranges tested
in extensive one-way sensitivity analyses. Probabilistic sensitivity
analysis revealed a probability of = 67% of an ICER below this
threshold in all countries. CONCLUSIONS: From the British,
Swedish, Italian and Belgian payer perspective, DRV/r 600/
100 mg bid is predicted to be cost-effective versus LPV/r in the
management of LPV/r-naïve, PI-resistant, HIV-infected adults
with a broad range of prior PI use/failure.
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OBJECTIVES: Ten years ago, Canada switched from whole cell
to acellular pertussis vaccine (AcE) from the whole cell product
(WCE) due to superior efﬁcacy and safety, but at an increased
cost. We performed a pharmacoeconomic analysis from societal
(direct+indirect costs) and Ministry of Health (MoH; direct costs
only) perspectives for Canadian children, comparing costs and
outcomes before and after the switch. METHODS: An epidemio-
logic model was constructed to portray the costs and outcomes
for a cohort of children born 1991–1996 compared with another
cohort born 1999–2004. The years between constituted the tran-
sition period. The model extended until children were age 13
(expected coverage period of pediatric immunization for pertus-
sis). Direct costs included vaccines and disease management
(pediatrician visits, emergency room visits, pediatric ICU and
ward stays, antibiotics). Indirect costs included parental time for
vaccination and hospital visits. Cost values were applied from
standard lists and projected to constant 2005 dollars, with costs
form other years discounted at 5%. Literature estimates were
used for infection rates, mortality rates, and clinical rates
(vaccine success, adverse events). Outcomes examined were per-
tussis cases avoided and pertussis hospitalizations avoided, both
discounted at 5%. Pharmacoeconomic outcomes were the incre-
mental costs per case avoided. Robustness of results was tested
with a variety of one-way and multivariate sensitivity analyses.
RESULTS: The total MoH was $238 million for WCE and $256
million for AcE; total societal costs were $540 million and $510
million, respectively. Cases decreased from 246,063 with WCE
to 106,088 with AcE and hospital admissions from 1038 to 441.
The MoH incremental cost/case avoided was $108 ($0.96/child).
From the societal perspective, there were cost savings. Sensitivity
analyses conﬁrmed that results were robust. CONCLUSIONS:
We found that pertussis vaccination with AcE was cost saving
from the societal perspective and cost-effective from the Ministry
of Health perspective.
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OBJECTIVES: To determine the cost-effectiveness of 7-valent
PCV in a national immunisation programme in Turkey.
METHODS: A model was developed in MS-Excel™ to estimate
the incidence of four diseases: pneumococcal meningitis, pneu-
mococcal septicaemia/bacteraemia, all-cause pneumonia and all-
cause acute otitis media in a cohort of children zero to ten years
of age. The efﬁcacy of the vaccine against these conditions was
assumed to be 97.4%, 97.4%, 7% and 6% respectively. In addi-
tion, corresponding adult disease burden was incorporated into
the model by assuming reductions of 32%, 8% and 18% in the
age groups 20–39 yrs, 40 to 64 yrs and 65 + yrs respectively, due
to indirect (herd) effects. Turkish data used were from reports of
the Ministry of Health, the Turkish Statistics Organisation, data
from 11 major hospitals in Istanbul (serving about 80% of the 12
million city population), the National Burden of Disease Survey
and the Verbal Autopsy Study. When Turkish data were not
available, estimates were developed through expert opinion
and/or extrapolated data. When paediatric costs were not known
they were assumed to be one-tenth of UK costs; when adult costs
were not known they were assumed to be one-ﬁfth of UK costs.
It was estimated that 1972 annual adult deaths occured due to
pneumococcal infection in Turkey. The estimated serotype cov-
erage for invasive pneumococcal diseases was 63% for those
<2 yrs of age and 35% for those 2 to 10 yrs of age. It was
assumed that only 80% of the primary birth cohort would be
vaccinated and the schedule would be 4 doses. RESULTS: The
addition of indirect (herd) effects to the model reduced the cost-
effectiveness by 12.5%. If one-tenth of the recognised cost-
effectiveness threshold (US$60,000 cost per life-year gained) is
taken as the cost-effectiveness threshold for Turkey ie US$6000,
then 7-valent PCV would be cost effective at a cost-per-dose of
US$45. The costs per QALY in Turkey for the treatment of
lung cancer is US$6141 and for hepatitis C treatment US$6638.
CONCLUSIONS: The inclusion of 7-valent PCV in a fully-
funded Turkish national immunisation programme would be
highly cost-effective.
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OBJECTIVES: The purpose of this study is to evaluate cost-
effectiveness and cost-utility of peginterferon alfa-2a (PEGASYS)
plus ribavirin (PEGIFN+RIB) versus no treatment, in HIV/HCV
co-infected patients in Portugal. METHODS: A 9-state Markov
model was developed to simulate the disease progression based
on the APRICOT clinical trial population (40-year old patients
with HIV/HCV co-infection; genotypes 1, 2/3 and 1/2/3) using
the METAVIR scoring system to stage liver disease. The model
included the following health states: no ﬁbrosis; portal ﬁbrosis,
no septa; portal ﬁbrosis, few septa; septal ﬁbrosis, no cirrhosis;
cirrhosis; decompensated cirrhosis; hepatocellular carcinoma;
liver transplant and death. The ﬁbrosis progression rates, transi-
tion probabilities and quality of life estimates were obtained
from reference studies. Efﬁcacy in terms of sustained virologi-
cal response for PEGIFN+RIB therapy was obtained from
APRICOT clinical trial. A lifetime horizon was considered. The
analysis assumes the National Health System perspective. Portu-
guese clinical practice was characterized from a consensus
experts panel, including patients’ diagnosis and follow-up, geno-
type distribution and main resources used. Unit costs were
obtained from ofﬁcial data. Costs and outcomes were discounted
by three percent annually. One-way sensitivity analysis was per-
formed on non-HCV treatment costs, time horizon, genotype
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